Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2023, Vol. 28 ›› Issue (11): 1275-1282.doi: 10.12092/j.issn.1009-2501.2023.11.010

Previous Articles     Next Articles

Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD 

LIU Lu1, SHI Yufei1, HE Qingfeng1, XU Fengyan2, WANG Kun2, CAI Weimin1, XIANG Xiaoqiang1   

  1. 1 Department of Clinical Pharmacy, School of Pharmacy, Fudan University, 2 Shanghai Qiangshi Information Technology Co., Ltd, Shanghai 200032, China
  • Received:2022-10-28 Revised:2023-05-23 Online:2023-11-26 Published:2023-11-10

Abstract:

Polymorphism refers to the simultaneous and frequent existence of two or more discontinuous variants or genotypes or alleles in a biological population, also known as genetic polymorphisms or genes Polymorphism. This gene polymorphism may have a certain degree of influence on the pharmacokinetics and pharmacodynamics of the drug. The study of genomics plays an important role in realizing personalized, patient-oriented precision medicine treatment. Population model analysis is to use a modeling method to quantitatively describe the correlation and variability between pharmacokinetic and pharmacodynamic parameters and individual characteristics and to quantify the impact of covariates. At present, this method has been widely used. This paper systematically introduces the application examples of using the population model approach to assess the effects of genetic polymorphisms on the drug PK/PD.

Key words: quantitative pharmacology, genetic polymorphism, population pharmacokinetics

CLC Number: